This Article Abstract Full Text (PDF) All Versions of this Article: 46/4/1039    most recent 01.HYP.0000174593.88899.68v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nagai, Y. Articles by Nishiyama, A. Search for Related Content PubMed PubMed Citation Articles by Nagai, Y. Articles by Nishiyama, A.

(Hypertension. 2005;46:1039.)
© 2005 American Heart Association, Inc.

Part 2 Original Articles

Aldosterone Stimulates Collagen Gene Expression and Synthesis Via Activation of ERK1/2 in Rat Renal Fibroblasts

Yukiko Nagai; Kayoko Miyata; Guang-Ping Sun; Matlubur Rahman; Shoji Kimura; Akira Miyatake; Hideyasu Kiyomoto; Masakazu Kohno; Youichi Abe; Masanori Yoshizumi; Akira Nishiyama

From Research Equipment Center (Y.N., A.M.), RI Research Center (K.M.), Second Department of Internal Medicine (G.-P.S., M.R., H.K., M.K.), and Department of Pharmacology (M.R., S.K., Y.A., A.N.), Kagawa Medical University, Kagawa, Japan; Department of Pharmacology (M.Y.), Nara Medical University School of Medicine, Nara, Japan.

Correspondence to Dr Akira Nishiyama, Department of Pharmacology, Kagawa Medical University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan. E-mail akira{at}kms.ac.jp

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Recently, we demonstrated that in rats treated chronically with aldosterone and salt, severe tubulointerstitial fibrosis is associated with the activation of mitogen-activated protein kinases (MAPKs), including extracellular signal-regulated kinases (ERK1/2). Here, we investigated whether aldosterone stimulates collagen synthesis via ERK1/2-dependent pathways in cultured rat renal fibroblasts. Gene expression of mineralocorticoid receptor (MR) and types I, II, III, and IV collagen was measured by real-time polymerase chain reaction (PCR). MR protein expression and ERK1/2 activity were evaluated by Western blotting analysis with anti-MR and anti–phospho-ERK1/2 antibodies, respectively. Collagen synthesis was determined by [³H]-proline incorporation. Significant levels of MR mRNA and protein expression were observed in rat renal fibroblasts. Treatment with aldosterone (0.1 to 10 nmol/L) increased ERK1/2 phosphorylation in a concentration-dependent manner with a peak at 5 minutes. Aldosterone (10 nmol/L) also increased the mRNA levels of types I, III, and IV collagen at 36 hours but had no effect on the type II collagen mRNA level. [³H]-proline incorporation was significantly increased by aldosterone in both the medium and cell layer at 48 hours. Aldosterone-induced ERK1/2 phosphorylation was markedly attenuated by pretreatment with eplerenone (10 µmol/L), a selective MR antagonist, or PD98059 (10 µmol/L), a specific inhibitor of MAPK kinase/ERK kinase, which is the upstream activator of ERK1/2. In addition, both eplerenone and PD98059 prevented the aldosterone-induced increases in types I, III, and IV collagen mRNA and [³H]-proline incorporation. These results suggest that aldosterone stimulates collagen gene expression and synthesis via MR-mediated ERK1/2 activation in renal fibroblasts, which may contribute to the progression of aldosterone-induced tubulointerstitial fibrosis.

Key Words: aldosterone • collagen • fibroblasts • mineralocorticoids

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Recent studies have indicated the usefulness of mineralocorticoid receptor (MR) antagonists in ameliorating renal injury.^1–13 In stroke-prone spontaneously hypertensive rats⁴ and rats treated with angiotensin II and a nitric oxide synthase inhibitor,⁵ cyclosporine A,⁶ or radiation,⁷ MR antagonists had no effect on systemic blood pressure but markedly ameliorated glomerular and tubulointerstitial fibrosis. In clinical studies, the addition of a nonselective MR antagonist, spironolactone, to angiotensin-converting enzyme inhibitors had no hemodynamic effects but markedly reduced proteinuria in patients with chronic renal failure⁸ and early diabetic nephropathy.⁹ It has also been shown that monotherapy with spironolactone¹⁰ or eplerenone,¹¹ a selective MR antagonist, is more effective than angiotensin-converting enzyme inhibitors in reducing proteinuria in hypertensive patients. Furthermore, White et al¹² showed that in hypertensive patients, eplerenone had a similar blood pressure–lowering effect to that of a calcium antagonist, amlodipine, but reduced the urinary albumin-to-creatinine ratio to a greater extent. These observations suggest that MR blockade has renoprotective effects through mechanisms that cannot be simply explained by blood pressure and hemodynamic changes.

Recently, we reported that in rats, chronic treatment with aldosterone and salt resulted in severe tubulointerstitial fibrosis with an increased renal collagen content, and that these effects of aldosterone were prevented by concurrent treatment with eplerenone.¹³ Interestingly, we also found that tubulointerstitial injury and collagen accumulation were associated with the activation of mitogen-activated protein kinases, including extracellular signal-regulated kinases (ERK)1/2.¹³ These data suggest that aldosterone/MR contributes to the pathogenesis of tubulointerstitial fibrosis through ERK1/2-dependent pathways.

In the present study, we hypothesized that aldosterone/MR may stimulate collagen synthesis through the activation of ERK1/2 in renal fibroblasts. To test this hypothesis, we first investigated whether MR is expressed in cultured rat renal fibroblasts. Next, we examined the effects of aldosterone on ERK1/2 phosphorylation, as well as collagen gene expression and synthesis in the renal fibroblasts. Finally, we examined the effects of eplerenone and PD98059, a specific inhibitor of mitogen-activated protein kinase/ERK kinase, which is the upstream activator of ERK1/2,¹⁴ on the aldosterone-induced collagen gene expression and synthesis.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Cell Culture
Rat renal fibroblasts (NRK-49F) were purchased from Dainippoin Pharmaceutical, Co Ltd and maintained according to published methods.¹⁵ Control solutions always contained an appropriate amount (<1:1000 dilution for each) of vehicle: ethanol for aldosterone (Across Organics), DMSO for eplerenone (Pfizer Inc) and PD98059 (Merck KGaA), and distilled water for cycloheximide (Sigma Chemical Co). At subconfluence, the culture medium was replaced with serum-free medium for 24 to 30 hours to render the cells quiescent. After stimulation, protein or mRNA was extracted as previously described.^16,17 Protein concentrations were determined using Bradford protein assay kits (Bio-Rad Laboratories).

Western Blotting Analysis
MR protein expression was determined by Western blotting analysis with an MR-specific antibody (Santa Cruz Biotechnology), as previously described in detail.^16,18 To evaluate activated ERK1/2, immunoblotting was performed with an antibody against phospho-ERK1/2 (Cell Signaling Technology), as previously described.^13,16,17 Total ERK1/2 protein expression was measured using a pan-ERK1/2 antibody (Cell Signaling Technology).^13,16,17 All values were normalized by arbitrarily setting the densitometry of control samples to 1.0.

Polymerase Chain Reaction
The mRNA expression levels of MR, collagen types I, II, III, and IV and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were analyzed by real-time polymerase chain reaction (PCR), as described previously.^13,17 Briefly, cDNA was initially denatured at 95°C for 30 seconds, and then amplified by PCR for 40 cycles (95°C for 15 seconds, 60°C for 40 seconds). The primer sequences are summarized in the Table. All data are expressed as the relative differences between control and treated cells after normalization to the GAPDH expression. The PCR product for MR (190 bp) was also electrophoresed in 2% agarose gels in Tris-bobate EDTA buffer and then stained with ethidium bromide.

View this table: [in this window] [in a new window]   Primer Sequences and Product Size

Proline Incorporation
[³H]-proline incorporation was used for a marker of collagen synthesis.^19–23 The levels of radiolabeled soluble collagen in the conditioned medium and nonsoluble collagen in the cell layer were determined.^19,20

Statistical Analysis
Values are presented as the mean±SE. One-way analysis of variance was used to determine the significance of differences among groups, after which a modified t test with the Bonferroni correction was used for comparisons between individual groups. P<0.05 was considered statistically significant.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Expression of MR in Rat Renal Fibroblasts
Western blotting analysis with an MR-specific antibody yielded a prominent band of 110 kDa in lysates obtained from rat renal fibroblasts (Figure 1A). When immunoblotting was performed in the presence of the primary antibody and the peptide fragment of MR was used to generate the primary antibody (Santa Cruz Biotechnology), the observed band was displaced, confirming that the binding was specific for MR (Figure 1A).

View larger version (36K): [in this window] [in a new window]   Figure 1. A, Mineralocorticoid receptor (MR) protein expression in rat renal fibroblasts, measured by Western blotting analysis. Significant MR protein expression is detected at 110 kDa in lysates of rat renal fibroblasts. The band is not present when incubating the blot with a mixture of the primary antibody and the antigenic-specific peptides. Representative data from 2 of 5 samples are shown. B, Amplification of MR mRNA by RT-PCR. The PCR product for MR (190 bp) was electrophoresed in 2% agarose gels in Tris-bobate EDTA buffer and stained with ethidium bromide as described in Material and Methods. C, Effects of aldosterone on MR mRNA expression in rat renal fibroblasts, measured by real-time PCR. Treatment with aldosterone has not effect on the MR mRNA level in renal fibroblasts. All data are expressed as the relative differences after normalization to the GAPDH expression.

As shown in Figure 1B, reverse-transcription PCR analysis revealed significant expression of the MR product (190 bp) in renal fibroblasts (n=5). Treatment with aldosterone (10 nmol/L) for 6 to 48 hours did not affect the MR mRNA level in renal fibroblasts (n=6 for each time point, Figure 1C).

ERK1/2 Phosphorylation
Aldosterone-induced (10 nmol/L) phosphorylation of ERK1/2 peaked at 5 minutes (2.0±0.2-fold) and continued for 30 minutes (n=7 to 9 for each time point) (Figure 2A). Figure 2B shows the concentration-dependent effects of aldosterone treatment (5 minutes) on the ERK1/2 phosphorylation. Aldosterone-stimulated ERK1/2 phosphorylation was found to be maximal at 10 nmol/L (n=7 to 10 for each concentration). However, no significant differences in the amounts of total (phosphorylated and unphosphorylated) ERK1/2 were observed in samples by Western blotting analysis with an anti-pan-ERK1/2 antibody (Figure 2A and 2B).

View larger version (30K): [in this window] [in a new window]   Figure 2. A, Time course of aldosterone-stimulated extracellular signal-regulated kinases (ERK)1/2 phosphorylation in rat renal fibroblasts. Rat renal fibroblasts were stimulated with 10 nmol/L aldosterone for the indicated times. B, Aldosterone stimulates ERK1/2 phosphorylation in rat renal fibroblasts in a concentration-dependent manner. Rat renal fibroblasts were stimulated with the indicated concentrations of aldosterone. The results were normalized by arbitrarily setting the densitometry of vehicle-treated cells (0 minutes or 0 nmol/L, respectively) to 1.0. *P<0.05 vs 0 minutes or 0 nmol/L, respectively.

To investigate the contribution of MR to the aldosterone-induced ERK1/2 activation, the effects of a selective MR antagonist, eplerenone,¹ on ERK1/2 phosphorylation were examined. Renal fibroblasts were pretreated with eplerenone (10 µmol/L) for 60 minutes before stimulation with aldosterone (10 nmol/L). Treatment with eplerenone prevented the aldosterone-induced ERK1/2 phosphorylation at 5 minutes (n=6) (Figure 3). To investigate the role of protein synthesis in the aldosterone-induced stimulation of ERK1/2, renal fibroblasts were pre-incubated with cycloheximide (10 µg/mL) for 15 minutes. However, cycloheximide had no effect on the aldosterone-induced ERK1/2 phosphorylation at 5 minutes (n=6) (Figure 3). However, pre-incubation with a mitogen-activated protein kinase/ERK kinase inhibitor, PD98059 (10 µmol/L for 30 minutes), prevented the aldosterone-induced ERK1/2 phosphorylation (n=6). The concentrations and pre-incubation times of eplerenone, cycloheximide, and PD98059 were determined on the basis of results from previous in vitro studies.^16,21,24,25

View larger version (20K): [in this window] [in a new window]   Figure 3. Effects of cycloheximide, eplerenone, and PD98059 on aldosterone-induced ERK1/2 phosphorylation in rat renal fibroblasts. Cycloheximide has no effect on the aldosterone-induced ERK1/2 phosphorylation. In contrast, aldosterone-induced ERK1/2 phosphorylation is prevented by pretreatment with eplerenone or PD98059. The results were normalized by arbitrarily setting the densitometry of vehicle-treated cells to 1.0. *P<0.05 vs vehicle.

Collagen Gene Expression
Figure 4 shows the effects of aldosterone on the mRNA levels of types I, II, III, and IV collagen (n=7 to 9 for each). Treatment with aldosterone (10 nmol/L) significantly increased the mRNA levels of types I (175±14% of the control), III (177±9% of the control), and IV (261±30% of the control) collagen, with peaks at 36 hours, but had no effect on the type II collagen mRNA level. Pretreatment with eplerenone (10 µmol/L) or PD98059 (10 µmol/L) prevented the aldosterone-induced increases in the mRNA levels of types I, III, and IV collagen (Figure 5) (n=9 for each).

View larger version (28K): [in this window] [in a new window]   Figure 4. Effects of aldosterone on the mRNA expression levels of types I, II, III, and IV collagen. Aldosterone significantly increases the mRNA levels of types I, III, and IV collagen, with peaks at 36 hours, but has no effect on the level of type II collagen mRNA. All data are expressed as the relative differences after normalization to the GAPDH expression. *P<0.05 vs 0 hours (vehicle treatment).

View larger version (23K): [in this window] [in a new window]   Figure 5. Effects of eplerenone and PD98059 on aldosterone-induced collagen mRNA expression in rat renal fibroblasts. Pretreatment with eplerenone or PD98059 prevents the aldosterone-induced increases in the mRNA levels of types I, III, and IV collagen. All data are expressed as the relative differences after normalization to the GAPDH expression. *P<0.05 vs vehicle.

Collagen Synthesis
The effects of aldosterone on collagen synthesis were evaluated by [³H]-proline incorporation in rat renal fibroblasts (n=11 for each) (Figure 6). Treatment with aldosterone (10 nmol/L) for 48 hours significantly increased [³H]-proline incorporation in the conditioned medium (135±11% of the control) and cell layer (135±14% of the control). These aldosterone-induced increases in [³H]-proline incorporation were inhibited by pre-incubation with eplerenone or PD98059.

View larger version (14K): [in this window] [in a new window]   Figure 6. Effects of eplerenone and PD98059 on aldosterone-induced collagen synthesis, evaluated by [3H]-proline incorporation. Aldosterone treatment significantly increases [3H]-proline incorporation in the conditioned medium and cell layer. These aldosterone-induced increases in [3H]-proline incorporation are inhibited by pre-incubation with eplerenone or PD98059. *P<0.05 vs vehicle.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
Aldosterone has been reported to induce collagen synthesis in cultured cardiac fibroblasts,^22,23 vascular smooth muscle cells,²¹ and glomerular mesangial cells.²⁶ However, to the best of our knowledge, there has been no direct evidence showing that aldosterone directly stimulates collagen gene expression and/or synthesis in renal fibroblasts. The present study demonstrated that cultured rat renal fibroblasts express both MR mRNA and protein. The results further revealed that aldosterone directly stimulates collagen gene expression and synthesis in renal fibroblasts. In addition, the effects of aldosterone were prevented by pretreatment with the selective MR antagonist, eplerenone.¹ Taken together, these data support the hypothesis that aldosterone/MR plays an important role in the pathophysiology of collagen accumulation in renal fibroblasts.

In the present study, we measured [³H]-proline incorporation as an index of collagen synthesis, because it has been shown that both labeled soluble proteins secreted into the medium and cell-associated proteins reflect the newly synthesized collagen.^19,20 However, this method does not provide any information on the individual collagen types involved. Several clinical studies have reported that interstitial mRNA expression of fiber-forming collagens (collagen types I and III) and collagen type IV, which is usually situated in cell basement membranes, is significantly increased in patients with renal fibrosis.^27,28 Interestingly, it was also demonstrated that the increased amounts of renal interstitial collagens were co-localized with fibroblasts.²⁸ These findings suggest that fibroblasts play a role in renal fibrosis through the synthesis of types I, III, and IV collagen. In the present study, aldosterone increased the gene expression of collagen types I, III, and IV in renal fibroblasts. However, the specific contributions of these aldosterone-induced collagens gene expression to the pathophysiology of renal fibrosis remain unclear, and further studies are necessary to address these issues.

ERK1/2 is an important mediator of the intracellular signal transduction pathway responsible for collagen synthesis in cardiovascular tissues, including the kidney.¹⁴ Pat et al²⁹ revealed that tubulointerstitial fibrosis induced by unilateral ureteral obstruction was associated with ERK1/2 phosphorylation in rats. Interestingly, unilateral ureteral obstruction–induced tubulointerstitial fibrosis was reported to be markedly attenuated by treatment with spironolactone, suggesting that aldosterone/MR may contribute to its pathogenesis.³⁰ Recently, we showed that aldosterone-induced tubulointerstitial fibrosis and collagen accumulation were associated with the activation of ERK1/2 in rats.¹³ Furthermore, the aldosterone-induced tubulointerstitial fibrosis and ERK1/2 activation were prevented by concurrent treatment with eplerenone, suggesting that aldosterone/MR induces tubulointerstitial fibrosis through the activation of ERK1/2. In the present study, aldosterone-induced collagen gene expression and synthesis were prevented by pretreatment with eplerenone or the mitogen-activated protein kinase/ERK kinase inhibitor, PD98059.¹⁴ These data combined with those of the previous animal experiments¹³ indicate that ERK1/2 is an important mediator of aldosterone-induced collagen synthesis in renal fibroblasts, which may contribute to the pathogenesis of aldosterone/MR-induced tubulointerstitial fibrosis.

In addition to its classical genomic actions mediated through regulation of nuclear gene transcription and protein synthesis, aldosterone also elicits rapid, potentially nongenomic responses in a variety of cells.^{16,21,24,31,32} Therefore, we examined the effects of cycloheximide, an inhibitor of protein synthesis,^25,32 on the aldosterone-induced ERK1/2 phosphorylation. The results revealed that cycloheximide had no effect on the rapid aldosterone-induced phosphorylation of ERK1/2, suggesting that nongenomic mechanisms are involved in aldosterone-induced ERK1/2 activation. We also observed that pre-incubation with eplerenone significantly attenuated the rapid effect of aldosterone on ERK1/2 in rat fibroblasts. These observations are consistent with those of recent studies showing that MR antagonists block aldosterone-induced activation of ERK1/2 in mesangial cells¹⁶ and Chinese hamster ovary cells transfected with human MR.³¹ Similarly, MR antagonists prevented aldosterone-induced p38 mitogen-activated protein kinase activation²¹ and angiotensin II–induced ERK1/2 activation²⁴ in vascular smooth muscle cells. However, Rossol-Haseroth et al²⁵ reported that the effects of aldosterone on ERK1/2 phosphorylation were unaffected by MR antagonists in cortical collecting duct cells. At present, we can find no satisfactory explanation for the discrepancies among these results. However, they may arise because of differences in the experimental conditions or cell types. Spironolactone has been shown to markedly attenuate the rapid aldosterone-induced activation of Ki-RasA³³ and c-Src,²¹ activators of the ERK1/2 cascade. In addition, MR antagonists are able to block several nongenomic actions of aldosterone on vascular Na⁺K⁺-ATPase³⁴ and arterial.^35,36 Based on these observations,^{16,21,24,31–36} together with the results of the present study, we speculate that in addition to its role as a transcription factor, MR could be involved, at least partially, in a cell signaling system involving the ERK1/2 pathway in rat renal fibroblasts.

Perspectives
The present study provides evidence, for the first time to our knowledge, that MR is actually expressed in renal fibroblasts, and that it is involved in aldosterone-induced collagen gene expression and synthesis. These data indicate that renal fibroblasts are one of the major targets for aldosterone/MR. In addition, these data may help to explain recent clinical observations indicating that MR antagonists have blood pressure-independent renoprotective effects.^8–12 The results of the present study further suggest that ERK1/2 is an important mediator of aldosterone/MR-induced collagen synthesis. Future studies are required to elucidate the precise molecular mechanisms by which aldosterone/MR mediates collagen synthesis in renal fibroblasts.

	Acknowledgments

 
This work was supported by a grant-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (15790136 and 17790171), and by grants from the Salt Sciences Research Grant (05C2), Pfizer Inc, the Japan Research Foundation for Clinical Pharmacology, and the Kao Foundation for Arts and Sciences (to A.N.).

Received April 28, 2005; first decision May 17, 2005; accepted June 1, 2005.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Rudolph AE, Rocha R, McMahon EG. Aldosterone target organ protection by eplerenone. Mol Cell Endocrinol. 2004; 217: 229–238.[CrossRef][Medline] [Order article via Infotrieve]
2. Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int. 2004; 66: 1–9.[CrossRef][Medline] [Order article via Infotrieve]
3. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003; 63: 1791–1800.[CrossRef][Medline] [Order article via Infotrieve]
4. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension. 1998; 31: 451–458.[Abstract/Free Full Text]
5. Rocha R, Stier CT Jr., Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 2000; 141: 3871–3878.[Abstract/Free Full Text]
6. Feria I, Pichardo I, Juarez P, Ramirez V, Gonzalez MA, Uribe N, Garcia-Torres R, Lopez-Casillas F, Gamba G, Bobadilla NA. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int. 2003; 63: 43–52.[Medline] [Order article via Infotrieve]
7. Brown NJ, Nakamura S, Ma L, Nakamura I, Donnert E, Freeman M, Vaughan DE, Fogo AB. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int. 2000; 58: 1219–1227.[CrossRef][Medline] [Order article via Infotrieve]
8. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med. 2001; 345: 925–926.[Free Full Text]
9. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003; 41: 64–68.[Abstract/Free Full Text]
10. Rachmani R, Slavachevsky I, Amit M, Levi Z, Kedar Y, Berla M, Ravid M. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med. 2004; 21: 471–475.[CrossRef][Medline] [Order article via Infotrieve]
11. Williams GH, Burgess E, Kolloch RE, Ruilope LM, Niegowska J, Kipnes MS, Roniker B, Patrick JL, Krause SL. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol. 2004; 93: 990–996.[CrossRef][Medline] [Order article via Infotrieve]
12. White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, Weber MA. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension. 2003; 41: 1021–1026.[Abstract/Free Full Text]
13. Nishiyama A, Yao L, Nagai Y, Miyata K, Yoshizumi M, Kagami S, Kondo S, Kiyomoto H, Shokoji T, Kimura S, Kohno M, Abe Y. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension. 2004; 43: 841–848.[Abstract/Free Full Text]
14. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev. 2000; 52: 11–34.[Abstract/Free Full Text]
15. Huang JS, Guh JY, Chen HC, Hung WC, Lai YH, Chuang LY. Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J Cell Biochem. 2001; 81: 102–113.[CrossRef][Medline] [Order article via Infotrieve]
16. Nishiyama A, Yao L, Fan Y, Kyaw M, Kataoka N, Hashimoto K, Nagai Y, Nakamura E, Yoshizumi M, Shokoji T, Kimura S, Kiyomoto H, Tsujioka K, Kohno M, Tamaki T, Kajiya F, Abe Y. Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension. 2005; 45: 710–716.[Abstract/Free Full Text]
17. Nishiyama A, Yoshizumi M, Hitomi H, Kagami S, Kondo S, Miyatake A, Fukunaga M, Tamaki T, Kiyomoto H, Kohno M, Shokoji T, Kimura S, Abe Y. The SOD mimetic tempol ameliorates glomerular injury and reduces mitogen-activated protein kinase activity in Dahl salt-sensitive rats. J Am Soc Nephrol. 2004; 15: 306–315.[Abstract/Free Full Text]
18. Kalman BA, Spencer RL. Rapid corticosteroid-dependent regulation of mineralocorticoid receptor protein expression in rat brain. Endocrinology. 2002; 143: 4184–4195.[Abstract/Free Full Text]
19. Takahashi S, Lee MJ. Quantitative study of tissue collagen metabolism. Anal Biochem. 1987; 162: 553–561.[CrossRef][Medline] [Order article via Infotrieve]
20. Peterkofsky B, Diegelmann R. Use of a mixture of proteinase-free collagenases for the specific assay of radioactive collagen in the presence of other proteins. Biochemistry. 1971; 10: 988–994.[CrossRef][Medline] [Order article via Infotrieve]
21. Callera GE, Touyz RM, Tostes RC, Yogi A, He Y, Malkinson S, Schiffrin EL. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension. 2005; 45: 773–779.[Abstract/Free Full Text]
22. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol. 1994; 26: 809–820.[CrossRef][Medline] [Order article via Infotrieve]
23. Zhou G, Kandala JC, Tyagi SC, Katwa LC, Weber KT. Effects of angiotensin II and aldosterone on collagen gene expression and protein turnover in cardiac fibroblasts. Mol Cell Biochem. 1996; 154: 171–178.[CrossRef][Medline] [Order article via Infotrieve]
24. Mazak I, Fiebeler A, Muller DN, Park JK, Shagdarsuren E, Lindschau C, Dechend R, Viedt C, Pilz B, Haller H, Luft FC. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation. 2004; 109: 2792–2800.[Abstract/Free Full Text]
25. Rossol-Haseroth K, Zhou Q, Braun S, Boldyreff B, Falkenstein E, Wehling M, Losel RM. Mineralocorticoid receptor antagonists do not block rapid ERK activation by aldosterone. Biochem Biophys Res Commun. 2004; 318: 281–288.[CrossRef][Medline] [Order article via Infotrieve]
26. Wakisaka M, Spiro MJ, Spiro RG. Synthesis of type VI collagen by cultured glomerular cells and comparison of its regulation by glucose and other factors with that of type IV collagen. Diabetes. 1994; 43: 95–103.[Abstract]
27. Wiggins R, Goyal M, Merritt S, Killen PD. Vascular adventitial cell expression of collagen I messenger ribonucleic acid in anti-glomerular basement membrane antibody-induced crescentic nephritis in the rabbit. A cellular source for interstitial collagen synthesis in inflammatory renal disease. Lab Invest. 1993; 68: 557–565.[Medline] [Order article via Infotrieve]
28. Goumenos D, Tsomi K, Iatrou C, Oldroyd S, Sungur A, Papaioannides D, Moustakas G, Ziroyannis P, Mountokalakis T, El Nahas AM. Myofibroblasts and the progression of crescentic glomerulonephritis. Nephrol Dial Transplant. 1998; 13: 1652–1661.[Abstract/Free Full Text]
29. Pat B, Yang T, Kong C, Watters D, Johnson DW, Gobe G. Activation of ERK in renal fibrosis after unilateral ureteral obstruction: modulation by antioxidants. Kidney Int. 2005; 67: 931–943.[CrossRef][Medline] [Order article via Infotrieve]
30. Trachtman H, Weiser AC, Valderrama E, Morgado M, Palmer LS. Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstruction. J Urol. 2004; 172: 1590–1594.[Medline] [Order article via Infotrieve]
31. Grossmann C, Benesic A, Krug AW, Freudinger R, Mildenberger S, Gassner B, Gekle M. Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Mol Endocrinol. 2005; 19: 1697–1710.[Abstract/Free Full Text]
32. Funder JW. The nongenomic actions of aldosterone. Endocr Rev. 2005; 26: 313–312.[Abstract/Free Full Text]
33. Stockand JD, Meszaros JG. Aldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-RasA and MAPK1/2 signaling. Am J Physiol Heart Circ Physiol. 2003; 284: H176–H184.[Abstract/Free Full Text]
34. Alzamora R, Marusic ET, Gonzalez M, Michea L. Nongenomic effect of aldosterone on Na⁺,K⁺-adenosine triphosphatase in arterial vessels. Endocrinology. 2003; 144: 1266–1272.[Abstract/Free Full Text]
35. Liu SL, Schmuck S, Chorazcyzewski JZ, Gros R, Feldman RD. Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation. 2003; 108: 2400–2406.[Abstract/Free Full Text]
36. Uhrenholt TR, Schjerning J, Hansen PB, Norregaard R, Jensen BL, Sorensen GL, Skott O. Rapid inhibition of vasoconstriction in renal afferent arterioles by aldosterone. Circ Res. 2003; 93: 1258–1266.[Abstract/Free Full Text]

This article has been cited by other articles:

				W. Huang, C. Xu, K. W. Kahng, N. A. Noble, W. A. Border, and Y. Huang Aldosterone and TGF-{beta}1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells Am J Physiol Renal Physiol, June 1, 2008; 294(6): F1287 - F1295. [Abstract] [Full Text] [PDF]

				H. Nishimura, Y. Ito, M. Mizuno, A. Tanaka, Y. Morita, S. Maruyama, Y. Yuzawa, and S. Matsuo Mineralocorticoid receptor blockade ameliorates peritoneal fibrosis in new rat peritonitis model Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1084 - F1093. [Abstract] [Full Text] [PDF]

				H. Otani, F. Otsuka, K. Inagaki, M. Takeda, T. Miyoshi, J. Suzuki, T. Mukai, T. Ogura, and H. Makino Antagonistic effects of bone morphogenetic protein-4 and -7 on renal mesangial cell proliferation induced by aldosterone through MAPK activation Am J Physiol Renal Physiol, May 1, 2007; 292(5): F1513 - F1525. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 46/4/1039    most recent 01.HYP.0000174593.88899.68v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nagai, Y. Articles by Nishiyama, A. Search for Related Content PubMed PubMed Citation Articles by Nagai, Y. Articles by Nishiyama, A.